Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S)

被引：0
|
作者：
Jonasch, Eric
Hasanov, Elshad
Motzer, Robert J.
Hariharan, Subramanian
Choueiri, Toni K.
Huang, Bo
Haanen, John B. A. G.
Albiges, Laurence
Venugopal, Balaji
Schmidinger, Manuela
Larkin, James M. G.
Grimm, Marc-Oliver
Negrier, Sylvie
Wang, Jing
Mariani, Mariangela
Chudnovsky, Aleksander
di Pietro, Alessandra
Rini, Brian I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Pfizer Inc, New York, NY USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Boston, MA USA
[6] Pfizer Inc, Groton, CT 06340 USA
[7] Netherlands Canc Inst, Amsterdam, Netherlands
[8] Inst Gustave Roussy, Villejuif, France
[9] Univ Glasgow, Glasgow, Lanark, Scotland
[10] Med Univ Vienna, Vienna, Austria
[11] Royal Marsden NHS Fdn Trust, London, England
[12] Jena Univ Hosp, Jena, Germany
[13] Univ Lyon, Ctr Leon Berard, Lyon, France
[14] Pfizer Inc, Cambridge, MA USA
[15] Pfizer SRL, Milan, Italy
[16] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Albiges, Laurence
    Haanen, John B. A. G.
    Larkin, James M. G.
    Uemura, Motohide
    Pal, Sumanta K.
    Gravis, Gwenaelle
    Campbell, Matthew T.
    Penkov, Konstantin
    Lee, Jae-Lyun
    Ching, Keith A.
    Mu, Xinmeng Jasmine
    Wang, Xiao
    Zhang, Weidong
    Wang, Jing
    Chudnovsky, Aleksander
    di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Campbell, Matthew T.
    Alekseev, Boris Y.
    Uemura, Motohide
    Kollmannsberger, Christian K.
    Gravis, Gwenaelle
    Bjarnason, Georg A.
    Gurney, Howard
    Chung, Jinsoo
    Haanen, John B. A. G.
    Rini, Brian I.
    Larkin, James M. G.
    Schmidinger, Manuela
    Nole, Franco
    Chudnovsky, Aleksander
    Huang, Bo
    Hariharan, Subramanian
    di Pietro, Alessandra
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Donahue, Amber C.
    Rini, Brian I.
    Powles, Thomas
    Haanen, John B. A. G.
    Larkin, James
    Mu, Xinmeng Jasmine
    Pu, Jie
    Thomaidou, Despina
    Di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): Results from JAVELIN Renal 101
    Grimm, M-O.
    Oya, M.
    Choueiri, T. K.
    Schmidinger, M.
    Quinn, D. I.
    Mescam, G. Gravis
    Verzoni, E.
    Van den Eertwegh, A. J. M.
    di Pietro, A.
    Mariani, M.
    Wang, J.
    Thomaidou, D.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S690 - S691
  • [5] Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): results from JAVELIN Renal 101
    Grimm, Marc-Oliver
    Oya, Mototsugu
    Choueiri, Toni K.
    Schmidinger, Manuela
    Quinn, David
    Gravis-Mescam, Gwenaelle
    Verzoni, Elena
    Van den Eertwegh, Alfonsus
    Di Pietro, Alessandra
    Mariani, Mariangela
    Wang, Jing
    Thomaidou, Despina
    Albiges, Laurence
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 100 - 100
  • [6] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow- up results from JAVELIN Renal 101.
    Haanen, John B. A. G.
    Larkin, James
    Choueiri, Toni K.
    Albiges, Laurence
    Rini, Brian I.
    Atkins, Michael B.
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Efficacy and safety of avelumab plus axitinib (A plus Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Motzer, Robert J.
    Choueiri, Toni K.
    Rini, Brian I.
    Miyake, Hideaki
    Uemura, Hirotsugu
    Albiges, Laurence
    Fujii, Yosuke
    Umeyama, Yoshiko
    Wang Jing
    Mariani, Mariangela
    Schmidinger, Manuela
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
    Motzer, Robert J.
    Robbins, Paul B.
    Powles, Thomas
    Albiges, Laurence
    Haanen, John B.
    Larkin, James
    Mu, Xinmeng Jasmine
    Ching, Keith A.
    Uemura, Motohide
    Pal, Sumanta K.
    Alekseev, Boris
    Gravis, Gwenaelle
    Campbell, Matthew T.
    Penkov, Konstantin
    Lee, Jae Lyun
    Hariharan, Subramanian
    Wang, Xiao
    Zhang, Weidong
    Wang, Jing
    Chudnovsky, Aleksander
    di Pietro, Alessandra
    Donahue, Amber C.
    Choueiri, Toni K.
    NATURE MEDICINE, 2020, 26 (11) : 1733 - +
  • [9] Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
    Robert J. Motzer
    Paul B. Robbins
    Thomas Powles
    Laurence Albiges
    John B. Haanen
    James Larkin
    Xinmeng Jasmine Mu
    Keith A. Ching
    Motohide Uemura
    Sumanta K. Pal
    Boris Alekseev
    Gwenaelle Gravis
    Matthew T. Campbell
    Konstantin Penkov
    Jae Lyun Lee
    Subramanian Hariharan
    Xiao Wang
    Weidong Zhang
    Jing Wang
    Aleksander Chudnovsky
    Alessandra di Pietro
    Amber C. Donahue
    Toni K. Choueiri
    Nature Medicine, 2020, 26 : 1733 - 1741
  • [10] Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
    Choueiri, T. K.
    Motzer, R. J.
    Rini, B., I
    Haanen, J.
    Campbell, M. T.
    Venugopal, B.
    Kollmannsberger, C.
    Gravis-Mescam, G.
    Uemura, M.
    Lee, J. L.
    Grimm, M-O
    Gurney, H.
    Schmidinger, M.
    Larkin, J.
    Atkins, M. B.
    Pal, S. K.
    Wang, J.
    Mariani, M.
    Krishnaswami, S.
    Cislo, P.
    Chudnovsky, A.
    Fowst, C.
    Huang, B.
    di Pietro, A.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2020, 31 (08) : 1030 - 1039
12345